185 related articles for article (PubMed ID: 33523340)
1. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer.
Lee IS; Sahu D; Hur H; Yook JH; Kim BS; Goel A
Gastric Cancer; 2021 May; 24(3):655-665. PubMed ID: 33523340
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer.
Lee IS; Lee H; Hur H; Kanda M; Yook JH; Kim BS; Woo Y; Kodera Y; Kim K; Goel A
Clin Cancer Res; 2021 Apr; 27(8):2292-2300. PubMed ID: 33558424
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
[TBL] [Abstract][Full Text] [Related]
4. A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer.
Peng K; Chen E; Li W; Cheng X; Yu Y; Cui Y; Li Q; Wang Y; Xu X; Tang C; Gan L; Yu S; Liu T
J Cell Physiol; 2020 Jul; 235(7-8):5777-5786. PubMed ID: 32048287
[TBL] [Abstract][Full Text] [Related]
5. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma.
Wada Y; Shimada M; Yamamura K; Toshima T; Banwait JK; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
Hepatology; 2021 Sep; 74(3):1371-1383. PubMed ID: 33725402
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
7. A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.
Wada Y; Shimada M; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
Eur J Cancer; 2022 Mar; 163():66-76. PubMed ID: 35042069
[TBL] [Abstract][Full Text] [Related]
8. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
[TBL] [Abstract][Full Text] [Related]
9. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
10. Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients With Gastric Cancer.
Shimura T; Toden S; Kandimalla R; Toiyama Y; Okugawa Y; Kanda M; Baba H; Kodera Y; Kusunoki M; Goel A
Ann Surg; 2021 Nov; 274(5):e425-e434. PubMed ID: 31663973
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer.
Huo J; Wu L; Zang Y
J Immunol Res; 2021; 2021():5554342. PubMed ID: 34007851
[TBL] [Abstract][Full Text] [Related]
12. Establishment and validation of a prognostic nomogram based on a novel five-DNA methylation signature for survival in endometrial cancer patients.
Li X; Yin F; Fan Y; Cheng Y; Dong Y; Zhou J; Wang Z; Li X; Wang J
Cancer Med; 2021 Jan; 10(2):693-708. PubMed ID: 33350104
[TBL] [Abstract][Full Text] [Related]
13. "3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy.
An O; Song Y; Ke X; So JB; Sundar R; Yang H; Rha SY; Lee MH; Tay ST; Ong X; Tan ALK; Ng MCH; Tantoso E; Chen L; Tan P; Yong WP;
Cancer Res; 2021 May; 81(10):2788-2798. PubMed ID: 33558338
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer.
Cai WY; Dong ZN; Fu XT; Lin LY; Wang L; Ye GD; Luo QC; Chen YC
Theranostics; 2020; 10(19):8633-8647. PubMed ID: 32754268
[No Abstract] [Full Text] [Related]
15. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer.
Ma B; Li Y; Ren Y
Cancer Med; 2020 Jan; 9(1):335-349. PubMed ID: 31743579
[TBL] [Abstract][Full Text] [Related]
16. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.
Kim SK; Kim HJ; Park JL; Heo H; Kim SY; Lee SI; Song KS; Kim WH; Kim YS
Gastric Cancer; 2020 May; 23(3):473-482. PubMed ID: 31773340
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
Han C; Zhang C; Wang H; Li K; Zhao L
BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
[TBL] [Abstract][Full Text] [Related]
18. A genomewide transcriptomic approach identifies a novel gene expression signature for the detection of lymph node metastasis in patients with early stage gastric cancer.
Izumi D; Gao F; Toden S; Sonohara F; Kanda M; Ishimoto T; Kodera Y; Wang X; Baba H; Goel A
EBioMedicine; 2019 Mar; 41():268-275. PubMed ID: 30772302
[TBL] [Abstract][Full Text] [Related]
19. A DNA methylation signature to improve survival prediction of gastric cancer.
Peng Y; Wu Q; Wang L; Wang H; Yin F
Clin Epigenetics; 2020 Jan; 12(1):15. PubMed ID: 31959204
[TBL] [Abstract][Full Text] [Related]
20. A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer.
Lee IS; Ahn J; Kim K; Okugawa Y; Toiyama Y; Hur H; Goel A
Br J Cancer; 2021 Sep; 125(6):846-853. PubMed ID: 34163003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
